Recombinant human prothrombin (r-prothrombin) and recombinant mutant prothrombin with active site Asp419 substituted by Asn (D419N-prothrombin) were expressed in recombinant CHO cells, isolated and purified from the fermentation supernatant. The r-Prothrombin and D419N-prothrombin were digested by both Echis carinatus venom and Oxyuranus scutellatus venom. Prior to, during and after activation, generation of thrombin activity and the proteolytic degradation of the prothrombin polypeptide chain were analysed. Owing to the recombinant preparation and inactivity of D419N-prothrombin and its activation products, the proteolytic action of E.carinatus and O.scutellatus venoms could be studied without addition of thrombin inhibitor, without interference from autocatalytic digestion of prothrombin and in the absence of any other blood coagulation protease. The comparison between the activation of r-prothrombin and D419N-prothrombin by snake venoms permitted differentiation between proteolytic activation and autocatalytic conversion of prothrombin. Incubation of D419N-prothrombin with E.carinatus venom resulted in the generation of stable D419N-meizothrombin by hydrolysis of the peptide bond Arg320-De321. By contrast, O.scutellatus venom exhibited activity towards peptide bonds Arg320-De321 and Arg271-Thr272 and lower activity towards peptide bond Argl55-Serl56, thus converting D419-prothrombin into D419N-thrombin and also liberating Fragment-1, Fragment-2 and Fragment-1/2 activation peptide. Activation of r-prothrombin by E.carinatus and O.scutellatus venoms demonstrated the autocatalytic potential of prothrombin-derived molecules and indicated that meizothrombin hydrolysed the cleavage between Fragment-2 and thrombin A-chain in the meizothrombin molecule, but not in prothrombin, preferentially at position Arg284-Thr285. By contrast, both meizothrombin and thrombin exhibited no detectable activity towards peptide bond Arg320-De321 between thrombin A-and B-chain, although this site exhibits the optimum sequence for thrombin cleavage.
Introduction
Human prothrombin is the single polypeptide chain precursor of the blood clotting proteinase thrombin. Prothrombin contains 579 amino acid residues and is composed of several distinct domains: Fragment-l (residues 1-155), Fragment-2 (residues 156-271), thrombin A-chain (residues 272-320) and thrombin B-chain (residues 321-579). Thrombin (coagulation factor Ila) is the activation product of prothrombin (coagulation factor II) that initiates the final stages of blood coagulation. It is a serine protease that cleaves the fibrinogen molecule into fibrin monomers and activates coagulation factor XIII, which then catalyses fibrin crosslinking reactions. Thrombin also controls other reactions in the blood clotting system by a feedback mechanism and is a highly potent stimulant of platelet release (Lundblad et al, 1977) . In vivo thrombin is liberated when prothrombin is activated by Factor Xa, Factor V and calcium ions (Jackson and Nemerson, 1980) by hydrolysis of the Arg271-Thr272 and Arg320-Ile321 peptide bonds, yielding thrombin composed of thrombin A-chain and B-chain. Detailed in vitro analysis of prothrombin by die prothrombinase complex and Factor Xa alone revealed the prothrombin activation pathway (Stenn and Blout, 1972; Heldebrant et al, 1973a,b; Esmon and Jackson, 1974; Esmon et al., 1974a-c; Owen et al., 1974; Downing et al., 1975; Jackson et al, 1975; Magnusson et al., 1975; Taswell et al, 1975; Morita et al, 1976; Krishnaswamy et al, 1986 Krishnaswamy et al, , 1987 Rosing et al, 1986; Rosing and Tans, 1988; Jackson, 1994) . Figure 1 shows a schematic diagram of human prothrombin and summarizes the prothrombin activation pathway. The catalytic centre of thrombin is contained in the B-chain and comprises the amino acids His363, Asp419 and Ser525.
However, prothrombin can also become activated through effects of exogenous sources, such as snake venoms (Denson et al, 1971; Girolami et al, 1975; Morita et al, 1975; Novoa et al, 1980; Walker et al, 1980; Briet et al, 1982; Rhee et al, 1982; Speijer et al, 1986; Yukelson et al, 1991; Rosing and Tans, 1992; Tans and Rosing, 1993; Marsh, 1994) . Snake venoms contain a rich variety of factors affecting the haemostatic mechanism by action of coagulant enzymes and anticoagulant proteins (Marsh, 1994) . Snake venoms also affect platelets either by inducing or inhibiting platelet aggregation and cause haemorrhage via proteolysis of the blood vessel wall. Snake venoms exhibit potential as well as therapeutic and diagnostic applications. Thus, detailed information on the structure and function of snake venoms is essential.
The study of effects of activators on human coagulation factors, such as prothrombin, are limited owing to several complications. Even highly purified human prothrombin preparations may contain traces of other coagulation proteases, such as thrombin, Factor X and Factor Xa. Prothrombinderived molecules which result from activator action, such as meizothrombin, may exhibit a notable proteolytic activity. Thrombin itself exhibits a strong autocatalytic potential. In the past, much effort was necessary to develop experimental conditions and to produce results which were able to differentiate between prothrombin activation by proteases and autocatalytic processing (for a review, see Jackson, 1994) . Even in the presence of inhibitors the stability of transient prothrombin activation products was low (Doyle and Mann, 1990 ). Other studies used mutant prothrombin with selected cleavage sites modified to stabilize intermediate prothrombin activation products (Cote et al, 1994) . Crystallographic studies of thrombin and its complexes with ligands showed that active site Ser525 and His363 contribute to different thrombin-specific interactions (Stone et al, 1987; Rydel et al, 1991; Bode et al, 1992; Banner and Hadvarary, 1993; Stubbs and Bode, 1993) . The substitution of Asp 102 by Asn in trypsin, a serine protease with structural homology to thrombin, by site-directed mutagenesis yielded a lC^-fold fall of the activity (Craik et al, 1987a) with the structures of the mutant and native enzymes being almost the same (Craik et al, 1987b) . To retain as much as possible the native structure and functionality of prothrombin and thrombin but to eliminate thrombin activity, for this study (i) recombinant mutant prothrombin with active site Asp419 substituted by Asn (D419N-prothrombin) and (ii) recombinant human prothrombin (r-prothrombin) were expressed, purified and characterized. D419N-prothrombin and its activation products exhibited no proteolytic activity. Owing to recombinant preparation, any contamination with other plasma proteases of the blood clotting system was excluded. D419N-prothrombin and r-prothrombin were used as model substrates for functional characterization of prothrombin activators isolated from Echis carinatus venom (Bnetetal, 1982; Rheee/a/., 1982) and Oxyuranusscutellatus venom (Speijer et al, 1986) to test whether recombinant and inactive coagulation factors are useful tools to study the action of snake venoms and to differentiate between proteolytic activation and autocatalytic conversion of prothrombin.
Materials and methods

Materials
Prothrombin-activating proteases from E.carinatus venom and O.scutellatus venom were obtained from Pentapharm (Basle, Switzerland) and Sigma (St Louis, MO, USA), respectively, and were additionally purified by gel filtration as described previously (Owen and Jackson, 1973; Morita et al, 1976) .
Purified venom proteases were stabilized by addition of albumin. Polyclonal rabbit anti-human prothrombin immunoglobulin (Assera factor II) was obtained from Diagnostica Stago (Asnieres, France). Peroxidase-conjugated goat antirabbit IgG was purchased from Bio-Rad (Hercules, CA, USA).
Construction of expression vectors
The (3-galactosidase Noil fragment of plasmid pSVb (MacGregor and Caskey, 1989) was removed. The resulting plasmid pSV was digested with HindUl and Xbal, filled in with Klenow and religated to yield pSVD. The chemically synthesized multiple cloning site 5'-CCATGG ACAAGCTTAT CGATCCCGGG AATTCGGTAC CGTCGACCTG CAGGTG-CACG GGCCCAGATC TGACTGACTG A-3' was inserted via compatible cohesive ends into the unique Xhol site to yield pSV-ATG+2. The human prothrombin cDNA fragment from pTKemc-PT2 was cloned as a partial Ncol, complete Smal fragment into analogously digested pSV-ATG+2, yielding expression vector pSV-FTJ for recombinant human prothrombin. pTKemc-PT2 was constructed by insertion of the EcoSl FII cDNA fragment from pTKgpt-PTHBb (Falkner et al, 1992) into the EcoRI site of pTM3 (Moss et al, 1990) , yielding pTKemc-PTx. In order to fuse the prothrombin cDNA ATG initiator codon correctly with the ATG initiator codon provided by pTM3, oligonucleotide-directed mutagenesis was performed with pTKemc-PTx single-stranded DNA and oligonucleotide 5'-AGCCTCGGAC GTGCGCCATG GTATTATCGT-3', yielding pTKemc-PT2. Using pSV-FTI as template, and primers 5'-TAACTGACGG TCCTTGAGCT CCATGTTGGA AAA-GATCTAC ATC-3' and 5'-GCAGACACAC AGGGTGAATG TAGTCACTGA AGGCAACAGG CTTCTTCAGC TTCAT-CAGGG CAATATTCCG GTCCAGGTTC TCCCGC-3', a fragment carrying the Asp419 to Asn419 mutant was created by PCR. This fragment was inserted into EcoRV/OralTJ cut pSV-FII via its flanking £c/136II and DraUl sites, yielding expression vector pSVFII-Asn419 for D419N-prothrombin.
Transfection and cell culture CHO-DXB11 cells (Urlaub and Chasin, 1980) were co-transfected with pSVFTI/pSV-dhfr and SVFII-Asn419/pSV-dhfr, respectively, essentially as described (Graham and van der Eb, 1973) . Selection for stably transfected cells was performed as described previously (Fischer etal, 1994) . Highly r-prothrombin and D419N-prothrombin expressing clones were grown in a high cell density perfusion fermenter under serum-free conditions.
Purification of r-prothrombin and D419N-prothrombin
Recombinant human prothrombin (r-prothrombin) and recombinant prothrombin with active site converted Asp419 to Asn (D419N-prothrombin) were produced by fermentation of recombinant CHO cells, r-Prothrombin and D419N-prothrombin were isolated from fermentation supematants (Fischer et al, 1995) by combination of anion-exchange chromatography and calcium filtration (Figure 2 ). Purification of r-prothrombin and D419N-prothrombin resulted in the selection of both fully y-carboxylated (Fischer et al. 1995) and glycosylated (Fischer et al, 1996a) prothrombin molecules. Whereas r-prothrombin exhibited a coagulation activity of 8 units/mg protein, no prothrombin activity was detected for D419N-prothrombin. For comparison, purified human plasma-derived prothrombin exhibited a coagulation activity of 7.5 units/mg protein (Fischer et al, 1996a,b) . -66,300
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-36,500 . During incubation the thrombin activity was determined. Protein samples were separated by SDS-PAGE, blotted onto a nitrocellulose membrane and prothrombin-derived peptides were stained immunoenzymatically. Immunoenzymatically stained blots were further analysed by densitometry. Activation end-products were subjected to N-terminal amino acid sequence analysis. N-Terminal amino acid sequence analysis of peptides generated during activation was performed directly from blots on to a PVDF membrane using standard Edman chemistry in an Applied Biosystems Model 477A PepSequencer.
Electrophoretic analysis
Electrophoretic analysis of protein was performed under reducing and non-reducing conditions by SDS-PAGE in 12% acrylamide slab gels using the buffer system described by LaemmJi (1970) . Immunoblotting Polypeptides resolved by electrophoresis were transferred onto nitrocellulose membranes in 25 mM Tris, 192 mM glycine, 20% (v/v) methanol buffer (Towbin etai, 1979) . Visualization of prothrombin-related peptides was carried out by immunoenzymatic staining. As primary antibody, polyclonal rabbit antihuman prothrombin immunoglobulin was used in a dilution of 1:1000. As secondary antibody, peroxidase-conjugated affinitypurified goat anti-rabbit IgG was used in a dilution of 1:1000. Pre-stained molecular weight markers, separated by SDS-PAGE and blotted onto nitrocellulose membranes, were used for the estimation of the molecular weights of peptides.
Determination of prothrombin activity
The clotting activity of prothrombin was determined by a onestep prothrombin time test as described in detail previously (Fischer et ai, 1995) using a prothrombin standard to prepare the calibration curve. Prothrombin-derived molecules were detected by immunoblotting followed by immunoenzymatic staining.
Determination of thrombin activity
Thrombin activity was determined photometrically by the hydrolysis of the synthetic thrombin-specific chromogenic substrate AcOH-HD-CHG-Ala-Arg-pNA at 37°C in 50 mM Tris-HCl buffer, pH 8.0, containing 150 mM NaCl, 0.1% PEG 6000 and a final substrate concentration of 200 (i.M. The release of p-nitroaniline that resulted from the hydrolysis of the peptidylp-nitroanilide substrate was followed by measuring the increase in absorbance at 410 nm. A thrombin standard was used to prepare the calibration curve. Using assay times of 10 min the detection limit of thrombin was 2.5 ng/ml.
Results by Activation of r-prothrombin and D4l9N-prothrombin E.carinatus venom protease Activation of r-prothrombin and D419N-prothrombin by E.carinatus venom is shown in Figure 3 . Digestion of D419N-prothrombin resulted in two peptides, labelled 55K and 32K ( Figure 3A) . N-terminal amino acid sequence analysis of the final activation product resulted in the detection of the two sequences (i) Ala-Asn-Thr-Phe-Leu-Gla-Gla-Val and (ii) Ile-Val-Glu-Gly-Ser-Asp-Ala-Glu, indicating that generated D419N-meizothrombin was composed of the Fragment-1/ Fragment-2/A-chain polypetide (Fl/F2/A-chain, 55K peptide) and of the thrombin B-chain polypeptide (32K peptide). Thus, exclusively peptide bond Arg320-Ile321 of D419N-prothrombin localized between thrombin A-and B-chain was hydrolysed. Owing to conversion of active site Asp419 to Asn, no thrombin activity was detected at any time during activation. Electrophoretic analysis under non-reducing conditions of protein samples prior to, during and after incubation of D419N-prothrombin with E.carinatus venom protease resulted in the constant detection of a peptide with a molecular weight of 72 000, thus F1/F2/A-chain polypeptide and thrombin B-chain were still connected by the Cys293-Cys439 disulphide bond. By contrast, activation of r-prothrombin by E.carinatus venom resulted in a very different activation pattern ( Figure  3B ). First, r-prothrombin is converted into r-meizothrombin, composed of thrombin B-chain (32K peptide) and F1/F2/Achain polypeptide (55K peptide). The appearance of a 52K peptide, identified by N-terminal amino acid sequence analysis as Fl/F2-activation peptide, apparently resulted from autocatalytic action of generated r-meizothrombin. The Fl/F2/A-chain polypeptide is then further degraded into Fragment-1 (27K peptide), Fragment-2 (16K peptide) and thrombin A-chain by proteolytic action of prothrombin-derived activation products. The appearance of a 19K peptide, identified as F2/A-chain polypeptide, indicated the temporary accumulation of a polypeptide resulting from the hydrolysis at position Arg32O-Ile321 by E.carinatus venom and autocatalytic hydrolysis at position Argl55-Serl56. There was no detectable accumulation of prethrombin-2, indicating that E.carinatus venomcatalysed hydrolysis of the Arg320-Ile321 bond preceded cleavage of the peptide bond between Fragment-2 and thrombin A-chain. N-terminal amino acid sequence analysis of the final activation products identified Fragment-1, Fragment-2, thrombin B-chain and a shortened thrombin A-chain starting at Thr285 . Thus, the peptide bond Arg284-Thr295 had been cleaved autocatalytically. Electrophoresis under non-reducing conditions of the final activation product resulted in a polypep- tide with an apparent molecular weight of 36 000, indicating that thrombin A-and B-chains were still connected by the intermolecular disulphide bond to form an active r-thrombin molecule. In contrast to D419N-prothrombin activation, activity measurement during r-prothrombin activation resulted in the detection of proteolytic activity ( Figure 4A ). Maximum thrombin activity was found after 40 min of incubation. Figure 5 shows the activation of D419N-prothrombin and r-prothrombin by O.scutellatus venom. Early activation products of D419N-prothrombin by O.scutellatus venom are peptides with molecular weights of 55 000, 52 000, 36 000 and 32 000, labelled 55K, 52K, 36K and 32K peptides, respectively ( Figure 5A ). Owing to Asp419 -> Asn modification, no thrombin activity was generated. The main final degradation products are the 52K and 32K peptides. Amino acid sequence analysis revealed that the 52K peptide corresponded to the Fl/F2-activation peptide with the N-terminal sequence Ala-Asp-Thr-Phe-Leu-Gla-Gla-Val, while the 32K peptide represented the thrombin B-chain with the N-terminal sequence Ile-Val-Glu-Gly-Ser-Asp-Ala. The 55K peptide was identified as Fl/F2/A-chain polypeptide. Additionally, N-terminal sequence analysis of the final activation product resulted in the detection of the sequence Thr-AJa-Thr-SerGlu-Tyr-Gln, corresponding to the thrombin A-chain. Thus, peptide bonds between thrombin A-and B-chain (Arg320-Ile321) and between Fragment-2 and thrombin A-chain (Arg271-Thr272) have been cleaved by O.scutellatus venom with similar activities. This suggested that the temporarily appearance of a 36K peptide corresponds to prethrombin-2, composed of the linear sequence of mrombin A-and B-chain. This was confirmed by sequence analysis of the 36K peptide and electrophoretic analysis under non-reducing conditions (not shown). Prolonged proteolysis resulted in the appearance of a 27K and a 16K peptide, identified as Fragment-2 and Fragment-1, respectively, unveiling a third cleavage site between Argl55 and Serl56. Electrophoretic analysis of the activation products under non-reducing conditions resulted in the detection of polypeptides with molecular weights of 52 000, 36 000, 27 000 and 16 000 (not shown), confirming the generation of the Fl/F2-activation peptide, of thrombin (composed of A-and B-chain), of Fragment-2 and of Fragment-1 as final products, respectively.
Activation of r-prothrombin and D419N-prothrombin by O.scutellatus venom
By contrast, activation of r-prothrombin by O.scutellatus venom ( Figure 5B ) resulted in no substantial accumulation of the 52K peptide, but rapid formation of 55K, 36K, 32K, 27K and 16K peptides, identified as Fl/F2/A-chain polypeptide, thrombin A-B-chain polypeptide, thrombin B-chain, Fragment-1 and Fragment-2, respectively. Thus, early generation of active thrombin molecules was instantly followed by autocatalytic hydrolysis of the peptide bond Argl55-Serl56, liberating Fragment-1 (27K peptide) and Fragment-2 (16K peptide). This was confirmed by amino acid sequence analysis of activation products and by electrophoresis under non-reducing conditions (not shown). Since activations of D419N-prothrombin and r-prothrombin by O.scutellatus venom were performed at the same time and under identical experimental conditions, it appeared that generated thrombin molecules inactivated O.scutellatus venom, thus slowing the cleavage between thrombin A-and B-chain. Although O.scutellatus venom exhibited sufficient proteolytic activity towards peptide bond Arg32O-De321 in D419N-prothrombin ( Figure 5A ), about 25% of the final activation product of r-prothrombin was composed of prethrombin-2 (36K peptide). However, amino acid sequence analysis of prethrombin-2 resulted in the sequence Thr-PheGly-Ser-Gly-Glu-Ala, indicating that peptide bond Arg284-Thr285 within the thrombin A-chain was autocatalytically cleaved. This was confirmed by electrophoretic analysis ( Figure  5B) , showing a slight reduction in molecular weight of the 36K peptide after 120 min of incubation. However, accumulated prethrombin-2 was not further autocatalytically converted into thrombin by hydrolysis of the Arg320-Ile321 peptide bond between thrombin A-and B-chain. Activity measurement during r-prothrombin activation resulted in a steady increase in proteolytic activity ( Figure 4B ), confirming the generation of enzymatically active degradation products of r-prothrombin.
Discussion
The physiologically important activator of prothrombin is the complex consisting of factor Xa, factor Va, phospholipids and Ca 2+ ions (prothrombinase complex). Activations of prothrombin by the prothrombinase complex and by factor Xa alone have been studied in detail previously (for a review, see Jackson, 1994) . Two pathways for prothrombin activation have been predicted: activation can occur via prethrombin-2 and Fragment-1/Fragment-2, or via meizothrombin (Stenn and Blout, 1972; Heldebrant et ai, 1973a,b; Esmon and Jackson, 1974; Esmon et al, I974a-c; Owen et al., 1974; Downing et al, 1975; Jackson et al, 1975; Magnusson et al, 1975; Taswell et al, 1975; Morita et al, 1976; Krishnaswamy et al, 1986 Krishnaswamy et al, , 1987 Rosing et al, 1986; Rosing and Tans, 1988; Jackson, 1994) . However, prothrombin can also become activated through effects of exogenous sources, such as snake venoms (Denson et al, 1971; Girolami et al, 1975; Morita et al, 1975; Novoa et al, 1980; Walker et al, 1980; Briet et al, 1982; Rhee et al, 1982; Speijer et al, 1986; Yukelson et al, 1991; Rosing and Tans, 1992; Tans and Rosing, 1993; Marsh, 1994) . Judging from its mode of action in prothrombin activation, E.carinatus venom appears capable of cleaving the Glyl55-Serl56 and Arg320-Ile321 bonds (Morita etal, 1975; Briet et al, 1982; Tans and Rosing, 1993) 
in prothrombin.
Oxyuranus scutellatus venom appears capable of cleaving the Arg271-Thr272 and Arg320-Ile321 bonds (Speijer et al, 1986; Tans and Rosing, 1993) .
However, even highly purified human prothrombin preparations may contain traces of other coagulation proteases, such as thrombin and Factor Xa. Prothrombin-derived molecules, such as meizothrombin, may exhibit a notable proteolytic activity. Thrombin itself exhibits a strong autocatalytic potential.
In this study, the substitution of Asp419 by Asn in human prothrombin by mutagenesis and recombinant expression yielded D419N-prothrombin exhibiting no coagulant activity. Owing to recombinant preparation of prothrombin, other coagulation factors and plasma proteases were excluded. Proteolytic digestion of D419N-prothrombin by E.carinatus venom resulted the detection of only a single cleavage site between thrombin A-chain and B-chain. Inactive but structural stable D419N-meizothrombin was formed. Thus, previously reported E.carinatus venom cleavage site at prothrombin Glyl58-Serl59 (Briet et al, 1982) apparently resulted from additional protease contamination. Activation of r-prothrombin by E.carinatus venom confirmed previous results (Krishnaswamy et al, 1986; Rosing et al, 1986; Rosing and Tans, 1988 ) that meizothrombin exhibits proteolytic activity for cleavage of the peptide bonds between Fragment-2 and A-chain and between Fragment-1 and Fragment-2. This study showed, that at the start of r-prothrombin activation by E.carinatus venom, generated r-meizothrombin and r-prothrombin existed simultaneously in solution. However, no generation of prethrombin-2 was observed. Thus, our results indicate for the first time that meizothrombin cleaves a peptide bond between Fragment-2 and A-chain exclusively in meizothrombin and not in prothrombin. Analysis of r-prothrombin activation by E.carinatus venom under neither reducing nor non-reducing conditions resulted in the detection of the entire thrombin A-chain starting at position Thr272; however, a shortened thrombin A-chain starting at Thr285 was found. Apparently the peptide bond Arg284-Thr285 is preferentially cleaved in meizothrombin. Temporary accumulation of F2/A-chain polypeptide indicates that autocatalytic cleavage of the Argl55-Serl56 bond occurs faster than hydrolysis between Fragment-2 and thrombin A-chain.
Incubation of D419N-prothrombin with O.scutellatus venom confirmed (Speijer et al, 1986; Tans and Rosing, 1993 ) that this enzyme catalyses the hydrolysis of prothrombin Arg32O-Ile321 and Arg271-Thr272 peptide bonds at similar rates, yielding simultaneous formation of meizothrombin, prethrombin-2 and thrombin. However, continuation of digestion resulted in the additional detection of activity towards the Argl55-Serl56 peptide bond. Activation of r-prothrombin by O.scutellatus venom confirmed that activated prothrombin-derived molecules catalyse the hydrolysis of Argl55-Serl56 bonds, thus preventing accumulation of Fl/F2-activation peptide. Interestingly, our results indicated for the first time that O.scutellatus venom protease is inactivated by thrombin and/or meizothrombin, resulting in the accumulation of prethrombin-2. Although the first 13 amino acids are released from thrombin A-chain of prethrombin-2 by an autocatalytic mechanism, prethrombin-2 was not autocatalytically converted into thrombin.
Previous studies of the activation pathway of prothrombin and meizothrombin included at least the addition of Factor Xa to human or bovine prothrombin solution (Stenn and Blout, 1972; Heldebrant et al, 1973; Esmon et al., 1974a,b; Owen et al, 1974; Jackson et al, 1975; Magnusson et al, 1975; Morita et al, 1976; Krishnaswamy et al, 1986 Krishnaswamy et al, , 1987 Rosing et al, 1986; Rosing and Tans, 1988) . The results of this study obtained in the absence of other coagulation factors show that meizothrombin itself has sufficient capacity for its own conversion into thrombin. By contrast, although the site between thrombin A-and B-chain exhibits an amino acid sequence favoured by thrombin (Chang, 1985) , apparently the Arg320-Ile321 peptide bond in prethrombin-2 is not recognized by activated prothrombin-derived molecules. Thus, hydrolysis of the Arg32O-Ile321 bond by Factor Xa appears to be the most important step in prothrombin activation.
In summary, the results of this study show that using recombinant and inactive prothrombins, the proteolytic actions of two different snake venoms were easily analysed. The combination of activation experiments of recombinant active and inactive prothrombin proved to be effective in obtaining detailed information about proteolytic properties of the coagulation factor itself and in differentiating clearly between protease action and autocatalytic function. Thus, the methods described in this paper offer several benefits over previous strategies for the functional characterization of coagulation factors and their activators.
